Branded Prescription Drugmakers

The thesis

Established prescription-drug franchises offer exposure to treatment demand rather than the pace of AI infrastructure spending. The current technology drawdown makes commercial medicine revenues and pipeline execution a timely diversification focus, while Lilly's reimbursement debate highlights the importance of volume growth versus net pricing. This basket spans metabolic, immune, cancer and infectious-disease medicines, but remains exposed to reimbursement pressure, patent expirations and clin